First-line pharmacologic therapy for trigeminal neuralgia?

• A. Carbamazepine
• B. Gabapentin
• C. Pregabalin
• D. Lamotrigine

Answer: (A)

Trigeminal neuralgia responds best to a sodium channel–blocking anticonvulsant as first-line therapy because it directly reduces the hyperexcitability of the trigeminal nerve that drives its sudden, shock-like facial pains. Carbamazepine has the strongest and most consistent evidence showing significant pain relief for these paroxysmal attacks, often with rapid improvement as dosing is titrated upward from a low starting amount.

Mechanistically, carbamazepine stabilizes neuronal membranes by inhibiting voltage-gated sodium channels, which decreases repetitive firing and ectopic discharges from the affected nerve fibers. This effect translates into fewer and less intense pain episodes for many patients. In practice, treatment starts at a low dose and is gradually increased to achieve symptom control while monitoring for adverse effects and drug interactions.

Common side effects include dizziness, drowsiness, double vision, and ataxia. There’s also a risk of hyponatremia and, in certain populations, rare but serious skin reactions. If carbamazepine is not tolerated or fails to control pain, other agents like gabapentin or pregabalin or lamotrigine can be considered, but they typically don’t have as strong a track record for this specific condition and carry their own side-effect profiles.